CN1235579C - 用于预防或治疗神经变性疾病的氨基甲酸酯化合物 - Google Patents

用于预防或治疗神经变性疾病的氨基甲酸酯化合物 Download PDF

Info

Publication number
CN1235579C
CN1235579C CNB028087178A CN02808717A CN1235579C CN 1235579 C CN1235579 C CN 1235579C CN B028087178 A CNB028087178 A CN B028087178A CN 02808717 A CN02808717 A CN 02808717A CN 1235579 C CN1235579 C CN 1235579C
Authority
CN
China
Prior art keywords
disease
formula
injury
use according
neurodegenerative diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028087178A
Other languages
English (en)
Chinese (zh)
Other versions
CN1503667A (zh
Inventor
C·R·普拉塔-萨拉曼
赵柏羽
R·E·特伊曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3 Dimensional Pharmaceuticals Inc
Original Assignee
3 Dimensional Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3 Dimensional Pharmaceuticals Inc filed Critical 3 Dimensional Pharmaceuticals Inc
Publication of CN1503667A publication Critical patent/CN1503667A/zh
Application granted granted Critical
Publication of CN1235579C publication Critical patent/CN1235579C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
CNB028087178A 2001-02-27 2002-02-21 用于预防或治疗神经变性疾病的氨基甲酸酯化合物 Expired - Fee Related CN1235579C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27168201P 2001-02-27 2001-02-27
US60/271,682 2001-02-27
US10/081,764 2002-02-21
US10/081,764 US20020165273A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
CN1503667A CN1503667A (zh) 2004-06-09
CN1235579C true CN1235579C (zh) 2006-01-11

Family

ID=26765943

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028087178A Expired - Fee Related CN1235579C (zh) 2001-02-27 2002-02-21 用于预防或治疗神经变性疾病的氨基甲酸酯化合物

Country Status (26)

Country Link
US (3) US20020165273A1 (https=)
EP (1) EP1383489B1 (https=)
JP (1) JP4276840B2 (https=)
KR (1) KR100910928B1 (https=)
CN (1) CN1235579C (https=)
AR (1) AR035756A1 (https=)
AT (1) ATE361745T1 (https=)
BR (1) BR0207645A (https=)
CA (1) CA2439295C (https=)
CY (1) CY1106753T1 (https=)
CZ (1) CZ301203B6 (https=)
DE (1) DE60220043T2 (https=)
DK (1) DK1383489T3 (https=)
ES (1) ES2284845T3 (https=)
HU (1) HUP0303264A3 (https=)
IL (2) IL157591A0 (https=)
MX (1) MXPA03007718A (https=)
MY (1) MY138156A (https=)
NO (1) NO20033798L (https=)
NZ (1) NZ527990A (https=)
PL (1) PL364680A1 (https=)
PT (1) PT1383489E (https=)
RS (1) RS51055B (https=)
RU (1) RU2300373C2 (https=)
TW (1) TWI312679B (https=)
WO (1) WO2002067925A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033093A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
CA2580640A1 (en) * 2004-09-16 2006-03-30 Janssen Pharmaceutica N.V. Methods of treating epileptogensis and epilepsy
MX2007004491A (es) * 2004-10-15 2007-08-08 Johnson & Johnson Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
AU2005335241B9 (en) * 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
CN101657195A (zh) * 2006-10-06 2010-02-24 詹森药业有限公司 氨基甲酸(s)-(+)-2-(2-氯代苯基)-2-羟基乙酯的新型晶体
CA2667949A1 (en) * 2006-10-30 2008-05-08 Janssen Pharmaceutica N.V. Methods for treating depression
MX2009004798A (es) * 2006-10-31 2009-08-12 Janssen Pharmaceutica Nv Tratamiento de los trastornos generalizados del desarrollo.
CA2803825C (en) * 2010-07-02 2015-12-29 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US20130060024A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
EP2797880B1 (en) * 2011-12-27 2017-03-01 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating epilepsy
EP2968210B1 (en) * 2013-03-12 2024-09-11 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
US9566261B2 (en) 2013-03-12 2017-02-14 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same
ES3059582T3 (en) 2016-02-29 2026-03-23 Bio Pharm Solutions Co Ltd Sulfamate derivative compounds, processes for preparing them and their uses
ES3035674T3 (en) 2016-12-14 2025-09-08 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
US20220117941A1 (en) * 2018-09-21 2022-04-21 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
JP2023539291A (ja) * 2020-08-31 2023-09-13 バイオ－ファーム ソリューションズ カンパニー リミテッド 神経変性疾患の予防又は治療用フェニルアルキルカルバメート化合物
KR20230051206A (ko) 2020-09-10 2023-04-17 (주)바이오팜솔루션즈 정신질환 치료 또는 완화용 설파메이트 유도체 화합물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3278380A (en) * 1962-02-06 1966-10-11 Armour Pharma Methods of calming employing diphenyl hydroxy carbamate compounds
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
CN1109880A (zh) * 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
MXPA03007717A (es) * 2001-02-27 2005-11-08 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o tratamiento de trastornos bipolares.
CN1262272C (zh) * 2001-02-27 2006-07-05 奥索-麦克尼尔药品公司 用于预防或治疗运动障碍的氨基甲酸酯化合物
US6541513B2 (en) * 2001-02-27 2003-04-01 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating psychotic disorders

Also Published As

Publication number Publication date
KR20030076714A (ko) 2003-09-26
DE60220043T2 (de) 2008-01-10
HUP0303264A2 (hu) 2004-01-28
DK1383489T3 (da) 2007-08-06
CY1106753T1 (el) 2012-05-23
CZ20032313A3 (cs) 2004-08-18
RU2300373C2 (ru) 2007-06-10
MXPA03007718A (es) 2004-11-12
IL157591A (en) 2009-12-24
CA2439295C (en) 2010-05-25
HUP0303264A3 (en) 2012-07-30
NZ527990A (en) 2006-01-27
JP4276840B2 (ja) 2009-06-10
EP1383489B1 (en) 2007-05-09
ES2284845T3 (es) 2007-11-16
RU2003128982A (ru) 2005-03-10
EP1383489A1 (en) 2004-01-28
AR035756A1 (es) 2004-07-07
PT1383489E (pt) 2007-06-21
ATE361745T1 (de) 2007-06-15
MY138156A (en) 2009-04-30
US20020165273A1 (en) 2002-11-07
NO20033798D0 (no) 2003-08-26
HK1060516A1 (en) 2004-08-13
RS67403A (sr) 2006-12-15
IL157591A0 (en) 2004-03-28
US20040171679A1 (en) 2004-09-02
KR100910928B1 (ko) 2009-08-06
BR0207645A (pt) 2004-12-28
US20090005442A1 (en) 2009-01-01
HK1065486A1 (en) 2005-02-25
WO2002067925A1 (en) 2002-09-06
CZ301203B6 (cs) 2009-12-09
JP2004523555A (ja) 2004-08-05
CN1503667A (zh) 2004-06-09
DE60220043D1 (de) 2007-06-21
TWI312679B (en) 2009-08-01
RS51055B (sr) 2010-10-31
NO20033798L (no) 2003-09-26
CA2439295A1 (en) 2002-09-06
PL364680A1 (en) 2004-12-13

Similar Documents

Publication Publication Date Title
CN1235579C (zh) 用于预防或治疗神经变性疾病的氨基甲酸酯化合物
JP5901528B2 (ja) 線維筋痛症候群の治療方法
KR101785072B1 (ko) 하지 불안 증후군의 치료방법
US20090137652A1 (en) Methods for neuroprotection
CN1250214C (zh) 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
JP2004527492A (ja) 運動障害の予防もしくは治療における使用のためのカルバメート化合物
CN1250215C (zh) 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
CN1262271C (zh) 用于预防或治疗精神病的氨基甲酸酯化合物
CN1250213C (zh) 用于预防或治疗神经性疼痛和丛集性头痛及有或没有先兆的偏头痛的氨基甲酸酯化合物
MX2007004491A (es) Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
AU2002247203B2 (en) Carbamate compounds for use in preventing or treating neurodegenerative disordrers
HK1065486B (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
RU2303445C2 (ru) Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью
HK1060516B (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
AU2002247203A1 (en) Carbamate compounds for use in preventing or treating neurodegenerative disordrers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1065486

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060111

Termination date: 20120221